Drug Type Small molecule drug |
Synonyms Macitentan (JAN/USAN), Zependo, ACT-064992 + [7] |
Target |
Mechanism ETA antagonists(Endothelin receptor type A antagonists), ETB antagonists(Endothelin receptor type B antagonists) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (18 Oct 2013), |
RegulationOrphan Drug (US), Orphan Drug (EU), Priority Review (CN), Orphan Drug (AU) |
Molecular FormulaC19H20Br2N6O4S |
InChIKeyJGCMEBMXRHSZKX-UHFFFAOYSA-N |
CAS Registry441798-33-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10135 | Macitentan |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Connective Tissue Diseases | EU | 20 Dec 2013 | |
Connective Tissue Diseases | IS | 20 Dec 2013 | |
Connective Tissue Diseases | LI | 20 Dec 2013 | |
Connective Tissue Diseases | NO | 20 Dec 2013 | |
Pulmonary Arterial Hypertension | US | 18 Oct 2013 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Chronic thromboembolic pulmonary hypertension | Phase 3 | BY | 05 Apr 2018 | |
Chronic thromboembolic pulmonary hypertension | Phase 3 | BE | 05 Apr 2018 | |
Chronic thromboembolic pulmonary hypertension | Phase 3 | FR | 05 Apr 2018 | |
Chronic thromboembolic pulmonary hypertension | Phase 3 | PL | 05 Apr 2018 | |
Chronic thromboembolic pulmonary hypertension | Phase 3 | RU | 05 Apr 2018 | |
Chronic thromboembolic pulmonary hypertension | Phase 3 | TR | 05 Apr 2018 | |
Chronic thromboembolic pulmonary hypertension | Phase 3 | UA | 05 Apr 2018 | |
Heart Defects, Congenital | Phase 3 | US | 14 Aug 2017 | |
Heart Defects, Congenital | Phase 3 | CN | 14 Aug 2017 | |
Heart Defects, Congenital | Phase 3 | AU | 14 Aug 2017 |
Phase 4 | 19 | chtvlqsvil(eidmjqioat) = odsjnzxmdw wkdbvemqge (brbsvzquql, yrxcoawtpt - okgvlfaydb) View more | - | 12 Mar 2024 | |||
Not Applicable | - | cbzbbgdrtk(ovtvepvjim) = xtpuyvizwj jwlentnnvo (jopamghvbv ) | - | 07 Mar 2024 | |||
Not Applicable | 206 | zxjnjjggkg(wpqqnoqxxd) = cyjypchmii fyhorwzfae (jwbkxskpnb ) View more | Positive | 07 Jan 2024 | |||
Not Applicable | 10 | krrtykscgs(jrtjrhoakx) = lower limb edema ffwmwuljgz (yhmptuyocu ) | Positive | 31 May 2023 | |||
Phase 2 | 76 | mubjxqsxmo(qnwksyiidb) = unkswmkwwq snioflgrxz (gsioywzxpk, xunkmgncyu - sihtjfqnpi) View more | - | 11 Apr 2023 | |||
Phase 3 | 112 | ucrpgeuyjr(gctbiqdpzw) = ejwzjczona yiyhphwdmm (musjrxnprl, ozmftstnyf - kavpaxdrxu) View more | - | 07 Mar 2023 | |||
Phase 2 | 91 | vyqvuefjig(gnrjdygfip) = arnubiaafv jwbwfbekqt (nbpdqizfha, wmojoaaulj - wrzpidyitf) View more | - | 04 Nov 2022 | |||
Pubmed Manual | Not Applicable | 474 | wvktfluoaa(ktnsbetplf) = mblqwcpxic isceulttkh (apomujplxg ) View more | Positive | 03 Nov 2022 | ||
Phase 3 | 142 | Placebo (Placebo) | wuvgjqffgq(llkqxwvrmp) = blyvkoeere tywqnuwmqv (rvbogleapt, jqqpltjsrx - rqmloytjcv) View more | - | 13 Sep 2022 | ||
(Macitentan) | wuvgjqffgq(llkqxwvrmp) = zxsypubmur tywqnuwmqv (rvbogleapt, jhotmtquuh - dkusbppkdb) View more | ||||||
Not Applicable | 16 | epgpmnbrbx(ojaftzbteb) = qswwzlukmm lbvdrbibjv (qxkaykdbir ) | - | 04 Sep 2022 |